Paul R. Gavine

AstraZeneca R&D
Shanghai, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

JNJ-79032421, a Novel Membrane-restricted Mesothelin-targeting T-cell-engaging Bispecific Antibody for the Treatment of Mesothelin-positive Cancers.

JNJ-79032421, a Novel Membrane-restricted Mesothelin-targeting T-cell-engaging Bispecific Antibody for the Treatment of Mesothelin-positive Cancers.

Journal: Molecular cancer therapeutics
Published: June 16, 2025

Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy.

Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy.

Journal: Nature communications
Published: September 01, 2021

Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL.

Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL.

Journal: Journal of medicinal chemistry
Published: July 19, 2021

Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.

Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.

Journal: Cell chemical biology
Published: February 21, 2020

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.

Journal: Molecular cancer therapeutics
Published: December 20, 2018

PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).

PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).

Journal: Oncotarget
Published: August 02, 2016

Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis.

Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis.

Journal: PloS one
Published: July 30, 2015

Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site.

Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site.

Journal: Acta crystallographica. Section D, Structural biology
Published: July 10, 2015

Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients.

Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients.

Journal: PloS one
Published: June 29, 2015

Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity.

Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity.

Journal: PloS one
Published: March 30, 2015

Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas.

Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas.

Journal: OncoTargets and therapy
Published: January 08, 2015

Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma.

Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma.

Journal: BMC cancer
Published: November 05, 2014
Showing 1-12 of 28

Last Updated: 09/26/2026